Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5565 for fibromyalgia pain
NL-OMON41747Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirogabalin in fibromyalgia (FM) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in weekly average daily pain score. Started Oct 2015; status: active, not recruiting.
02
Drugs
mirogabalin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NL-OMON41747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41747.